Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

5.97
-0.0850-1.40%
Volume:606.48K
Turnover:3.67M
Market Cap:878.04M
PE:-10.18
High:6.24
Open:6.09
Low:5.95
Close:6.05
52wk High:6.60
52wk Low:1.74
Shares:147.20M
Float Shares:110.00M
Volume Ratio:0.97
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:7.05
PE(LYR):-11.25

Loading ...

Aclaris Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 06

Aclaris Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
May 05

Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler

TIPRANKS
·
May 05

Aclaris Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
May 05

Damora Therapeutics names Brian Burkavage principal financial officer, accounting officer

Reuters
·
May 05

Aclaris Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
May 04

JTL Industries Wins ACRS Nod, Tightens Grip on Global Structural Steel Markets

TIPRANKS
·
May 04

Aclaris Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 30

Aclaris Therapeutics price target raised to $10 from $8 at Wedbush

TIPRANKS
·
Apr 29

Wedbush Raises Price Target on Aclaris Therapeutics to $10 From $8, Keeps Outperform Rating

MT Newswires Live
·
Apr 29

Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial

TIPRANKS
·
Apr 28

BRIEF-Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055

Reuters
·
Apr 28

Aclaris Therapeutics Inc - Enrollment Ongoing in Phase 1B Trials of ATI-052; Top Line Results Expected H2 2026

THOMSON REUTERS
·
Apr 28

Aclaris Therapeutics Inc - ATI-052 Well Tolerated With Favorable Safety Profile in Phase 1a Trial

THOMSON REUTERS
·
Apr 28

Aclaris Therapeutics Inc: No Impact of Anti-Drug Antibodies (Ada) on Pk or Pd Has Been Observed in This Trial

THOMSON REUTERS
·
Apr 28

BML Capital’s Braden Leonard sells 300,000 Aclaris shares for $1.36 million

Reuters
·
Apr 28

Aclaris to release Phase 1a ATI-052 trial results April 28

Reuters
·
Apr 28

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

GlobeNewswire
·
Apr 28

Aclaris Therapeutics announces upcoming annual shareholder meeting

Reuters
·
Apr 23

Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum

TIPRANKS
·
Apr 17